ProMIS Neurosciences News and Activities

ProMIS Neurosciences is a company listed under the stock ticker PMN (US).

View the org chart displaying its 16 main executives

Most searched biographies at ProMIS Neurosciences

• Neil Warma, President and Chief Executive Officer
• Eugene Williams, Chairman of the Board
• William Wyman, Director

Popular executive movements at ProMIS Neurosciences

• Slanix Alex has joined the company as Director  (posted on October 23 2025).

Create your alert
to follow the executive moves at ProMIS Neurosciences.

ProMIS Neurosciences has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by ProMIS Neurosciences

• ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
• ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
• ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
• ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
• ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
• ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
• ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
• ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
• ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
• ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
• View more press releases Close

Social media about ProMIS Neurosciences

• ProMIS Neurosciences on Wikipedia, Google News & Yahoo Finance
• ProMIS Neurosciences on LinkedIn, X (Twitter) & YouTube